Venus Remedies' Q2 FY 2026-27 Quarterly Results

Result Summary

• Venus Remedies Ltd reported a 20.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 12.8%.
• Its expenses for the quarter were up by 22.7% QoQ and 10.6% YoY.
• The net profit increased 11.7% QoQ and increased 27.4% YoY.
• The earnings per share (EPS) of Venus Remedies Ltd stood at 19.19 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Venus Remedies Ltd is a pharmaceutical company engaged in the manufacture and distribution of a wide range of pharmaceutical formulations, including antibiotics, oncology drugs, and other therapeutic areas. The company is known for its focus on research and development, contributing to a diverse product portfolio that addresses various medical needs. While specific recent developments are not available, Venus Remedies Ltd typically operates within the pharmaceutical industry, which is characterized by rigorous regulatory standards and ongoing research initiatives. The company's competitive landscape includes both domestic and international pharmaceutical firms, and it strives to maintain a strong market presence through innovation and quality assurance.

Revenue

In the second quarter of fiscal year 2027 (Q2FY27), Venus Remedies Ltd reported a total income of ₹219.27 crores. This represents a significant increase of 20.8% quarter-over-quarter (QoQ) from ₹181.48 crores in the first quarter of fiscal year 2027 (Q1FY27). Additionally, the total income experienced a year-over-year (YoY) growth of 12.8% compared to ₹194.46 crores in the second quarter of fiscal year 2026 (Q2FY26). This upward trajectory in revenue underscores the company's ability to generate substantial income over both short-term and annual periods.

Profitability

Venus Remedies Ltd's profitability metrics for Q2FY27 indicate a profit before tax (PBT) of ₹33.47 crores. This marks an 11.4% increase QoQ from ₹30.04 crores in Q1FY27 and a YoY rise of 26.3% from ₹26.49 crores in Q2FY26. The tax expense for Q2FY27 was ₹7.82 crores, showing a 10.6% increase QoQ from ₹7.07 crores in Q1FY27 and a 23.0% increase YoY from ₹6.36 crores in Q2FY26. Consequently, the profit after tax (PAT) for Q2FY27 amounted to ₹25.65 crores, reflecting an 11.7% QoQ growth from ₹22.97 crores and a 27.4% YoY increase from ₹20.13 crores. Earnings per share (EPS) for the same period also rose by 11.7% QoQ and 27.4% YoY, standing at ₹19.19.

Operating Metrics

The total expenses for Venus Remedies Ltd in Q2FY27 were ₹185.80 crores, which signifies a 22.7% QoQ increase from ₹151.44 crores in Q1FY27 and a 10.6% YoY growth from ₹167.97 crores in Q2FY26. This increase in expenses corresponds with the rise in total income, maintaining a consistent expenditure pattern relative to revenue growth. The company's operating efficiency can be evaluated by examining the proportional changes in income and expenses, which have both increased over the assessment periods. These metrics are instrumental in understanding the company's operational dynamics and financial health during this quarter.